Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma.

Molecular pharmaceutics·2026
Same author

CD70-targeted platform for diagnosing and treating multiple myeloma.

Journal for immunotherapy of cancer·2026
Same author

[18F]RCCB6 PET/CT in Diagnosing Clear Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.

Cancer discovery·2026
Same author

Trop2-Targeted [<sup>18</sup>F]AlF-RESCA-RT4 ImmunoPET/CT in Guiding Clinical Surgeries of Thyroid Cancers: A Proof-of-Concept Study.

Molecular pharmaceutics·2026
Same author

Immuno-PET Imaging of Tumor Mesothelin Expression with a Gallium-68 Radiolabeled Nanobody.

Molecular pharmaceutics·2026
Same author

Rational Design of Aptamer-Guided Framework Nucleic Acid Delivery Platform for Cancer Radionuclide Theranostics.

ACS nano·2025

Related Experiment Video

Updated: Oct 11, 2025

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K

Annotating BCMA Expression in Multiple Myelomas.

Weijun Wei1, You Zhang1, Di Zhang1

  • 1Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

Molecular Pharmaceutics
|November 29, 2021
PubMed
Summary
This summary is machine-generated.

New immunoPET imaging agents successfully visualize B cell maturation antigen (BCMA) in multiple myeloma (MM) models. These BCMA-targeted radiotracers enable precise diagnosis and monitoring of MM lesions.

Keywords:
BCMAImmunoPETcompanion diagnosticsmultiple myelomananobody

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.7K

Related Experiment Videos

Last Updated: Oct 11, 2025

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.7K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Molecular Imaging

Background:

  • B cell maturation antigen (BCMA) is a key target for multiple myeloma (MM) therapies.
  • Noninvasive imaging of BCMA is crucial for personalized treatment strategies.
  • Current imaging methods for BCMA dynamics are limited.

Purpose of the Study:

  • To develop and evaluate novel gallium-68 labeled nanobody-based immunoPET tracers targeting BCMA for MM diagnosis.
  • To assess the diagnostic efficacy of these tracers in preclinical MM models.
  • To enable noninvasive visualization of BCMA expression and MM lesions.

Main Methods:

  • Production and radiolabeling of BCMA-targeting nanobodies with Gallium-68 (68Ga).
  • Establishment of disseminated MM mouse models.
  • Evaluation of diagnostic performance using immunoPET imaging, biodistribution studies, and histopathology.

Main Results:

  • Two radiotracers, [68Ga]Ga-NOTA-MMBC2 and [68Ga]Ga-NOTA-MMBC3, were successfully developed with >99% radiochemical purity.
  • ImmunoPET imaging accurately visualized BCMA expression and MM lesions in bone marrow.
  • [68Ga]Ga-NOTA-MMBC3 detected residual MM after daratumumab treatment, correlating with biodistribution and IHC data.

Conclusions:

  • Developed novel 68Ga-labeled BCMA-targeting nanobodies ([68Ga]Ga-NOTA-MMBC2 and [68Ga]Ga-NOTA-MMBC3) for immunoPET imaging.
  • Demonstrated the potential of these tracers for precise diagnosis and monitoring of MM.
  • Further translational studies are warranted to confirm clinical utility in MM management.